Clinical trial
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
NCT00217022 · Mayo Clinic, Other · Terminated
Key facts
| NCT number | NCT00217022 |
|---|---|
| Title | Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis |
| Official title | A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | AstraZeneca Industry National Center for Research Resources (NCRR) NIH |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lymphocytic Colitis, Diarrhea |
| Intervention type | Drug, Other |
| Interventions | Placebo, Budesonide |
| Enrollment | 16 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 2, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: